713 related articles for article (PubMed ID: 28102226)
1. Chronic lymphocytic leukaemia.
Kipps TJ; Stevenson FK; Wu CJ; Croce CM; Packham G; Wierda WG; O'Brien S; Gribben J; Rai K
Nat Rev Dis Primers; 2017 Jan; 3():16096. PubMed ID: 28102226
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of chronic lymphocytic leukaemia.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Br J Haematol; 2019 Sep; 186(5):668-684. PubMed ID: 31364161
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukaemia: from genetics to treatment.
Bosch F; Dalla-Favera R
Nat Rev Clin Oncol; 2019 Nov; 16(11):684-701. PubMed ID: 31278397
[TBL] [Abstract][Full Text] [Related]
6. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
7. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukaemia: an immunobiology approach.
Kostareli E; Smilevska T; Stamatopoulos K; Kouvatsi A; Anagnostopoulos A
Srp Arh Celok Lek; 2008; 136(5-6):319-23. PubMed ID: 18792635
[TBL] [Abstract][Full Text] [Related]
9. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
10. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
[TBL] [Abstract][Full Text] [Related]
11. Biology and treatment of chronic lymphocytic leukemia.
Keating MJ; Chiorazzi N; Messmer B; Damle RN; Allen SL; Rai KR; Ferrarini M; Kipps TJ
Hematology Am Soc Hematol Educ Program; 2003; ():153-75. PubMed ID: 14633781
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
Stanganelli C; Travella A; Bezares R; Slavutsky I
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
14. Genetics and molecular biology of chronic lymphocytic leukemia.
Carney DA; Wierda WG
Curr Treat Options Oncol; 2005 May; 6(3):215-25. PubMed ID: 15869733
[TBL] [Abstract][Full Text] [Related]
15. The pathogenesis of chronic lymphocytic leukemia.
Zhang S; Kipps TJ
Annu Rev Pathol; 2014; 9():103-18. PubMed ID: 23987584
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukaemia.
Scarfò L; Ferreri AJ; Ghia P
Crit Rev Oncol Hematol; 2016 Aug; 104():169-82. PubMed ID: 27370174
[TBL] [Abstract][Full Text] [Related]
17. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction.
Landeira-Viñuela A; Arias-Hidalgo C; Juanes-Velasco P; Alcoceba M; Navarro-Bailón A; Pedreira CE; Lecrevisse Q; Díaz-Muñoz L; Sánchez-Santos JM; Hernández ÁP; García-Vaquero ML; Góngora R; De Las Rivas J; González M; Orfao A; Fuentes M
Front Immunol; 2022; 13():965905. PubMed ID: 36248816
[TBL] [Abstract][Full Text] [Related]
18. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
[TBL] [Abstract][Full Text] [Related]
19. What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?
Oppezzo P; Dighiero G
Curr Top Microbiol Immunol; 2005; 294():71-89. PubMed ID: 16323428
[TBL] [Abstract][Full Text] [Related]
20. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia.
Henriques A; Rodríguez-Caballero A; Nieto WG; Langerak AW; Criado I; Lécrevisse Q; González M; Pais ML; Paiva A; Almeida J; Orfao A
PLoS One; 2013; 8(7):e67751. PubMed ID: 23844084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
